Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Receivables (2018 - 2025)

Historic Receivables for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $80.7 million.

  • TransMedics' Receivables fell 1045.85% to $80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 1045.85%. This contributed to the annual value of $97.7 million for FY2024, which is 5370.89% up from last year.
  • Latest data reveals that TransMedics reported Receivables of $80.7 million as of Q3 2025, which was down 1045.85% from $107.5 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Receivables ranged from a high of $142.0 million in Q1 2025 and a low of $4.1 million during Q3 2021
  • Its 5-year average for Receivables is $52.1 million, with a median of $47.5 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 3242.14% in 2021, then surged by 43096.39% in 2022.
  • Over the past 5 years, TransMedics' Receivables (Quarter) stood at $5.9 million in 2021, then skyrocketed by 365.3% to $27.6 million in 2022, then skyrocketed by 130.26% to $63.6 million in 2023, then surged by 53.71% to $97.7 million in 2024, then decreased by 17.42% to $80.7 million in 2025.
  • Its Receivables was $80.7 million in Q3 2025, compared to $107.5 million in Q2 2025 and $142.0 million in Q1 2025.